Letter to the editor regarding the publication “Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review”
Rama Jayaraj,1 Chellan Kumarasamy2
1Clinical Sciences, College of Health and Human Sciences, Charles Darwin University, Casuarina, NT, Australia; 2University of Adelaide, Adelaide, SA, Australia
The authors of the article, “Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review”, Zhou et al, have put forth a number of interesting points.1 This paper, published in the journal Cancer Management and Research attempts to link matrix metalloproteinase (MMP) polymorphisms and the propensity to developing prostate cancer. Though a similar study has previously been done on ovarian cancer by authors credited in this study, this study does tread fresh ground on the topic of prostate cancer and has potential to act as a guideline for future research.
View the original paper by Zhou and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]